Profil
Mark Watson is currently the Director at H.
Lee Moffitt Cancer Center & Research Institute, Inc. since 2009.
He is also currently serving as an Independent Trustee at abrdn Healthcare Opportunities Fund starting in 2022.
Previously, Mr. Watson held positions as Director at Sykes Enterprises, Inc. from 2018 to 2021, Director at BioDelivery Sciences International, Inc. from 2017 to 2022, and Director at Inhibitor Therapeutics, Inc. from 2014 to 2022.
Aktive Positionen von Mark Watson
| Unternehmen | Position | Beginn |
|---|---|---|
| ABRDN HEALTHCARE OPPORTUNITIES FUND | Direktor/Vorstandsmitglied | 09.06.2022 |
H. Lee Moffitt Cancer Center & Research Institute, Inc.
H. Lee Moffitt Cancer Center & Research Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research & contributions to clinical trials, prevention and cancer control | Direktor/Vorstandsmitglied | 01.01.2009 |
Ehemalige bekannte Positionen von Mark Watson
| Unternehmen | Position | Ende |
|---|---|---|
| HEDGEPATH PHARMACEUTICALS INC | Direktor/Vorstandsmitglied | 13.12.2022 |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | Direktor/Vorstandsmitglied | 02.01.2022 |
| SYKES ENTERPRISES, INCORPORATED | Direktor/Vorstandsmitglied | 02.01.2021 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Sykes Enterprises, Inc.
Sykes Enterprises, Inc. Information Technology ServicesTechnology Services Provides business process outsourcing services | Technology Services |
BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology Operates as a commercial stage pharmaceutical company to patients living with chronic pain | Health Technology |
abrdn Healthcare Opportunities Fund
abrdn Healthcare Opportunities Fund Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
H. Lee Moffitt Cancer Center & Research Institute, Inc.
H. Lee Moffitt Cancer Center & Research Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research & contributions to clinical trials, prevention and cancer control | Commercial Services |
Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
















